T
Toragen repurposes antiviral drugs and develops novel immunotherapies to target viral-associated cancers. The company aims to improve treatment outcomes for patients suffering from malignancies linked to viral infections.
Updated 20 months ago
Funding
$6.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PE
Funding rounds are not available yet.
Founders
Product
Features
- Toragen repurposes antiviral drugs and develops novel immunotherapies to target viral-associated cancers. The company aims to improve treatment outcomes for patients suffering from malignancies linked to viral infections.